Toward a single dose cure for Buruli ulcer
Sangeeta Susan Thomas, Nitin Pal Kalia, Marie‐Thérèse Ruf, Gerd Pluschke, Kévin Pethe
bioRxiv (Cold Spring Harbor Laboratory) · 2020-04
Abstract
Abstract A single dose of TELACEBEC (Q203), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks post treatment. Clinical use of Q203 could dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
MeSH terms
- Buruli ulcer
- Mycobacterium ulcerans
- Tuberculosis
- Medicine
- Mycobacterium tuberculosis
- Dermatology
- Cutaneous tuberculosis
- Disease